Clinical Trial: NCT06211036
Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab
Status:
ACTIVE NOT RECRUITINGPhase:
Phase 3| Lead Sponsor: | Amgen |
| Information Provided By: | Amgen |
| Last Update Posted: | 2026-11-06 |
Study Overview
Brief Summary
The primary objective of this study is to compare the efficacy of tarlatamab plus durvalumab with durvalumab alone on prolonging overall survival (OS).
Official Title
A Phase 3, Open-label, Multicenter, Randomized Study of Tarlatamab in Combination With Durvalumab vs Durvalumab Alone in Subjects With Extensive-Stage Small-Cell Lung Cancer Following Platinum, Etoposide and Durvalumab (DeLLphi-305)
Conditions
Extensive-Stage Small-Cell Lung Cancer, Small-Cell Lung Cancer
Intervention / Treatment
- Drug: Tarlatamab
- Drug: Durvalumab
Other Study ID Numbers
- 20200041
- 2023-505989-29
- 2023
Start Date (Actual)
2024-06-05
Primary Completion Date (Estimated)
2030-04-02
Study Completion Date (Estimated)
2030-04-02
Enrollment (Actual)
563
Study Type
Interventional
Phase
Phase 3
| Lead Sponsor: | Amgen |
| Information Provided By: | Amgen |
| Last Update Posted: | 2026-11-06 |
Study Overview
Brief Summary
The primary objective of this study is to compare the efficacy of tarlatamab plus durvalumab with durvalumab alone on prolonging overall survival (OS).
Official Title
A Phase 3, Open-label, Multicenter, Randomized Study of Tarlatamab in Combination With Durvalumab vs Durvalumab Alone in Subjects With Extensive-Stage Small-Cell Lung Cancer Following Platinum, Etoposide and Durvalumab (DeLLphi-305)
Conditions
Extensive-Stage Small-Cell Lung Cancer, Small-Cell Lung Cancer
Intervention / Treatment
- Drug: Tarlatamab
- Drug: Durvalumab
Other Study ID Numbers
- 20200041
- 2023-505989-29
- 2023
Start Date (Actual)
2024-06-05
Primary Completion Date (Estimated)
2030-04-02
Study Completion Date (Estimated)
2030-04-02
Enrollment (Actual)
563
Study Type
Interventional
Phase
Phase 3